Teva Pharmaceutical Industries Limited (TEVA) |
|
10.265 0.015 (0.15%)
|
09-26 14:31 |
|
Open: |
10.19 |
Pre. Close: |
10.25 |
|
High:
|
10.4 |
Low:
|
10.19 |
|
Volume:
|
4,852,840 |
Market Cap:
|
11,506(M) |
|
|
|
Technical analysis |
as of: 2023-09-26 2:22:16 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 12.52 One year: 14.62 |
| Support: |
Support1: 9.81 Support2: 9.26 |
| Resistance: |
Resistance1: 10.72 Resistance2: 12.52 |
| Pivot: |
10.18  |
| Moving Average: |
MA(5): 10.38  MA(20): 10.06
MA(100): 8.65 MA(250): 8.98 |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 70.4 %D(3): 74.9 |
| RSI: |
RSI(14): 57.2 |
| 52-week: |
High: 11.44 Low: 7.09 |
| Average Vol(K): |
3-Month: 9,426 (K) 10-Days: 8,508 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TEVA ] has closed below upper band by 44.8%. Bollinger Bands are 40.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
10.33 - 10.38 |
10.38 - 10.42 |
|
Low:
|
9.89 - 9.96 |
9.96 - 10.01 |
|
Close:
|
10.15 - 10.26 |
10.26 - 10.34 |
|
Company Description |
|
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel. |
Headline News |
Tue, 26 Sep 2023
Challenges and Potential of Generic Drug Companies in Improving ... - Best Stocks
Tue, 26 Sep 2023
Should You Hold Teva Pharmaceutical Industries Ltd (TEVA) Stock Tuesday Morning? - InvestorsObserver
Tue, 26 Sep 2023
Harel Insurance Investments & Financial Services Ltd. Sells ... - MarketBeat
Tue, 26 Sep 2023
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given ... - MarketBeat
Mon, 25 Sep 2023
Intriguing Block Trade Unfolds in Financial Markets - Best Stocks
Mon, 25 Sep 2023
Nordea Investment Management AB Reduces Holdings in Teva ... - Best Stocks
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
1,120 (M) |
| Shares Float |
1,120 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
49.6 (%) |
|
Shares Short
|
16,900 (K) |
|
Shares Short P.Month
|
22,710 (K) |
Stock Financials |
|
EPS
|
-1.95 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
6.28 |
|
Profit Margin (%)
|
-14.9 |
|
Operating Margin (%)
|
16.5 |
|
Return on Assets (ttm)
|
3.4 |
|
Return on Equity (ttm)
|
-26.6 |
|
Qtrly Rev. Growth
|
2.4 |
|
Gross Profit (p.s.)
|
6.22 |
|
Sales Per Share
|
13.41 |
|
EBITDA (p.s.)
|
3.31 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
1,700 (M) |
|
Levered Free Cash Flow
|
3,080 (M) |
Stock Valuations |
|
PE Ratio
|
-5.3 |
|
PEG Ratio
|
2.9 |
|
Price to Book value
|
1.63 |
|
Price to Sales
|
0.76 |
|
Price to Cash Flow
|
6.76 |
Stock Dividends |
|
Dividend
|
0.09 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0.8% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
